ALIPAY+
1.2.2023 03:28:40 CET | Business Wire | Press release
Alipay+ has further strengthened its partnership with Asia’s largest food delivery platform, foodpanda, to Malaysia. Through this partnership, foodpanda Malaysia’s customers can now enjoy convenient food and grocery deliveries by paying through Touch ’n Go eWallet, one of the leading mobile wallets in Malaysia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230131005758/en/
Alipay+ has further strengthened its partnership with Asia’s largest food delivery platform, foodpanda, to Malaysia.
With contactless payments becoming more prevalent over the past few years, users of Touch ’n Go eWallet are now able to purchase food and daily essentials through foodpanda Malaysia, the country’s leading quick commerce delivery platform. Customers can also enjoy instant cash discount at checkout via Touch ‘n Go eWallet when placing orders on foodpanda.
“foodpanda Malaysia is committed to providing our customers with the convenience of having their food and daily essentials delivered right to their doorstep. We strive to be 1% better each time and add value to our customer’s experience. This time, it is to give them more options in payment methods,” said foodpanda Malaysia Chief Executive Officer Sayantan Das.
“We are proud to be partnering with Alipay+ and TNG Digital to enable the usage of Touch ’n Go eWallet on our platform. Leveraging our synergies as the leading quick commerce platform and the largest eWallet provider in the country, we are happy to play our role in encouraging the adoption of digital payment for the convenience and safety of millions of our merchants, riders and customers,” he added.
The gross merchandise value (GMV) of the on-demand food delivery market in Southeast Asia is expected to reach US$49.7 billion by 2030, growing at a compound annual growth rate of 14.1%, according to a 2022 report from research firm Frost & Sullivan. The GMV was estimated to be at US$15.2 billion in 2021, it said.
foodpanda Malaysia’s latest partnership with Touch ’n Go eWallet will tap into the eWallet’s more than 18 million registered users.
Commenting on the collaboration, Alan Ni, Chief Executive Officer of TNG Digital Sdn Bhd said, “We are very excited to partner with foodpanda to give our users access to a seamless and convenient delivery experience in Malaysia.
“Through Touch ’n Go eWallet, our users will be able to make payments for their orders with peace of mind knowing that their transactions are safe and secure,” he added.
Introduced by Ant Group in 2020, Alipay+ is a suite of cross-border digital payment, marketing and merchant digitization solutions connecting global brands with mobile-savvy consumers worldwide. Currently, 16 global e-wallet partners backed by Alipay+ have covered more than 1.3 billion digital-savvy consumers, mostly in Southeast Asia.
Alipay+ Rewards is a new digital marketing platform developed by Alipay+ and partner e-wallets to help global brands better engage with consumers worldwide by offering incentives and exclusive services.
Malaysia is the fifth major market in Asia where Alipay+ and foodpanda have collaborated to provide services with leading local mobile wallets in the region. Prior to this latest partnership in Malaysia, other Alipay+ partner e-wallets, including GCash in the Philippines, TrueMoney in Thailand, bKash in Bangladesh and AlipayHK in Hong Kong SAR, China, have already supported payments on their respective local foodpanda platforms.
Jing Yin, General Manager of Acquiring Service and Global Strategic Accounts of Ant Group, said: “Alipay+ is committed to helping merchants reach more than 1 billion global consumers and ensure easy and smooth payments of our e-wallet partners when consumers place orders on each platform.
“We are excited to offer payment and marketing solutions to foodpanda Malaysia through the Touch ’n Go eWallet, and we are looking forward to partnering with foodpanda in more markets by bringing more designated benefits with our local e-wallet partners in the future.”
About Alipay+
Alipay+ offers unified global mobile payment and marketing solutions that connect merchants with multiple e-wallets and payment methods from different countries and regions by collaborating with global partners. Consumers can conveniently use their preferred local payment methods while transacting seamlessly in a different market and be able to enjoy marketing solutions offered by the merchants through Alipay+. Alipay+ is developed by Ant Group, the owner and operator of Alipay, one of the world’s leading digital open platforms.
About foodpanda
foodpanda is a leading delivery platform in Asia Pacific dedicated to bringing consumers a wide range of food, groceries and more, quickly and conveniently. Powered by technology and operational excellence, foodpanda is spearheading the growth of quick-commerce (q-commerce) across the region with its network of retail partners, as well as pandamart cloud stores to provide more on-demand options beyond the millions of food delivery options. foodpanda operates in more than 300 cities across 11 markets in Asia Pacific - Singapore, Hong Kong, Thailand, Malaysia, Pakistan, Taiwan, Philippines, Bangladesh, Laos, Cambodia, and Myanmar. foodpanda is a subsidiary of Delivery Hero, a global leader in the food delivery industry. For more information, visit www.foodpanda.com.
About TNG Digital Sdn Bhd
TNG Digital Sdn Bhd (“TNGD”) was founded by Touch ‘n Go Sdn Bhd and Ant Group (“Ant”), parent company of Alipay, China’s largest digital payments platform. Established in 2017, TNGD is the owner and operator of Touch ‘n Go eWallet, Malaysia’s number one eWallet company, with more than 18 million registered users and over 1.2 million merchant touch points including DuitNow QR. Combining Touch ‘n Go’s strong domestic brand, dominance in toll, transit and parking use cases and nationwide user base, together with Ant’s deep domain expertise and leading the development of open platforms for technology-driven inclusive financial services, the Touch ‘n Go eWallet provides financial services and payments services to both retail users and small to mid-sized businesses, across physical and online infrastructure. For more information, please visit www.touchngo.com.my.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230131005758/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom